Search research articles
Contact Us
Filters
Showing results (11-20 of 17) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 17 results.
Genes & Cancer
|
June 16, 2012
Antitumor Activity of VB-111, a Novel Antiangiogenic Virotherapeutic, in Thyroid Cancer Xenograft Mouse Models
H V Reddi, P Madde, Y C Cohen, et al.
Cancer Research
|
May 16, 2000
Flavopiridol binds to duplex DNA
K C Bible, R H Bible, T J Kottke, et al.
Cancer Research
|
May 19, 2001
Loss of expression of a new member of the DNAJ protein family confers resistance to chemotherapeutic agents used in the treatment of ovarian cancer
V Shridhar, K C Bible, J Staub, et al.
Cancer Research
|
February 24, 2001
The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux
C Erlichman, S A Boerner, C G Hallgren, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 26, 2000
Characterization of an ovarian carcinoma cell line resistant to cisplatin and flavopiridol
K C Bible, S A Boerner, K Kirkland, et al.
The Journal of Clinical Endocrinology and Metabolism
|
April 17, 2013
Efatutazone, an oral PPAR-γ agonist, in combination with paclitaxel in anaplastic thyroid cancer: results of a multicenter phase 1 trial
R C Smallridge, J A Copland, M S Brose, et al.
The Journal of Biological Chemistry
|
July 31, 1999
Characterization of caspase processing and activation in HL-60 cell cytosol under cell-free conditions. Nucleotide requirement and inhibitor profile
P W Mesner, K C Bible, L M Martins, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 17) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 17 results.
Genes & Cancer
|
June 16, 2012
Antitumor Activity of VB-111, a Novel Antiangiogenic Virotherapeutic, in Thyroid Cancer Xenograft Mouse Models
H V Reddi, P Madde, Y C Cohen, et al.
Cancer Research
|
May 16, 2000
Flavopiridol binds to duplex DNA
K C Bible, R H Bible, T J Kottke, et al.
Cancer Research
|
May 19, 2001
Loss of expression of a new member of the DNAJ protein family confers resistance to chemotherapeutic agents used in the treatment of ovarian cancer
V Shridhar, K C Bible, J Staub, et al.
Cancer Research
|
February 24, 2001
The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux
C Erlichman, S A Boerner, C G Hallgren, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 26, 2000
Characterization of an ovarian carcinoma cell line resistant to cisplatin and flavopiridol
K C Bible, S A Boerner, K Kirkland, et al.
The Journal of Clinical Endocrinology and Metabolism
|
April 17, 2013
Efatutazone, an oral PPAR-γ agonist, in combination with paclitaxel in anaplastic thyroid cancer: results of a multicenter phase 1 trial
R C Smallridge, J A Copland, M S Brose, et al.
The Journal of Biological Chemistry
|
July 31, 1999
Characterization of caspase processing and activation in HL-60 cell cytosol under cell-free conditions. Nucleotide requirement and inhibitor profile
P W Mesner, K C Bible, L M Martins, et al.
Page
of 2